BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 39.6% in January

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a large decrease in short interest in January. As of January 15th, there was short interest totalling 50,400 shares, a decrease of 39.6% from the December 31st total of 83,400 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 48,500 shares, the days-to-cover ratio is currently 1.0 days.

BioCardia Price Performance

BCDA stock traded down $0.06 during trading on Thursday, reaching $2.32. 23,617 shares of the stock traded hands, compared to its average volume of 46,464. The business’s 50 day moving average price is $2.20 and its 200-day moving average price is $2.52. The firm has a market capitalization of $10.63 million, a PE ratio of -0.55 and a beta of 1.26. BioCardia has a 52-week low of $1.63 and a 52-week high of $8.85.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of BioCardia in a research report on Wednesday, December 18th.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.